Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immune responses during COVID-19 breakthrough cases in vaccinated children and adolescents.
Rivera-Pérez D, Méndez C, Diethelm-Varela B, Melo-González F, Vázquez Y, Meng X, Xin Q, Fasce RA, Fernández J, Mora J, Ramirez E, Acevedo ML, Valiente-Echeverría F, Soto-Rifo R, Grifoni A, Weiskopf D, Sette A, Astudillo P, Le Corre N, Abarca K, Perret C, González PA, Soto JA, Bueno SM, Kalergis AM. Rivera-Pérez D, et al. Front Immunol. 2024 May 15;15:1372193. doi: 10.3389/fimmu.2024.1372193. eCollection 2024. Front Immunol. 2024. PMID: 38812507 Free PMC article.
Humoral and cellular response induced by a second booster of an inactivated SARS-CoV-2 vaccine in adults.
Méndez C, Peñaloza HF, Schultz BM, Piña-Iturbe A, Ríos M, Moreno-Tapia D, Pereira-Sánchez P, Leighton D, Orellana C, Covarrubias C, Gálvez NMS, Soto JA, Duarte LF, Rivera-Pérez D, Vázquez Y, Cabrera A, Bustos S, Iturriaga C, Urzua M, Navarrete MS, Rojas Á, Fasce RA, Fernández J, Mora J, Ramírez E, Gaete-Argel A, Acevedo M, Valiente-Echeverría F, Soto-Rifo R, Weiskopf D, Grifoni A, Sette A, Zeng G, Meng W; CoronaVac03CL Study Group; González-Aramundiz JV, González PA, Abarca K, Melo-González F, Bueno SM, Kalergis AM. Méndez C, et al. Among authors: rivera perez d. EBioMedicine. 2023 May;91:104563. doi: 10.1016/j.ebiom.2023.104563. Epub 2023 Apr 24. EBioMedicine. 2023. PMID: 37099842 Free PMC article.
Inactivated Vaccine-Induced SARS-CoV-2 Variant-Specific Immunity in Children.
Soto JA, Melo-González F, Gutierrez-Vera C, Schultz BM, Berríos-Rojas RV, Rivera-Pérez D, Piña-Iturbe A, Hoppe-Elsholz G, Duarte LF, Vázquez Y, Moreno-Tapia D, Ríos M, Palacios PA, Garcia-Betancourt R, Santibañez Á, Pacheco GA, Mendez C, Andrade CA, Silva PH, Diethelm-Varela B, Astudillo P, Calvo M, Cárdenas A, González M, Goldsack M, Gutiérrez V, Potin M, Schilling A, Tapia LI, Twele L, Villena R, Grifoni A, Sette A, Weiskopf D, Fasce RA, Fernández J, Mora J, Ramírez E, Gaete-Argel A, Acevedo ML, Valiente-Echeverría F, Soto-Rifo R, Retamal-Díaz A, Muñoz-Jofré N; PedCoronaVac03CL Study Group,; Meng X, Xin Q, Alarcón-Bustamante E, González-Aramundiz JV, Le Corre N, Álvarez-Figueroa MJ, González PA, Abarca K, Perret C, Carreño LJ, Bueno SM, Kalergis AM. Soto JA, et al. Among authors: rivera perez d. mBio. 2022 Dec 20;13(6):e0131122. doi: 10.1128/mbio.01311-22. Epub 2022 Nov 16. mBio. 2022. PMID: 36383021 Free PMC article.
Differences in the immune response elicited by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial.
Gálvez NMS, Pacheco GA, Schultz BM, Melo-González F, Soto JA, Duarte LF, González LA, Rivera-Pérez D, Ríos M, Berrios RV, Vázquez Y, Moreno-Tapia D, Vallejos OP, Andrade CA, Hoppe-Elsholz G, Iturriaga C, Urzua M, Navarrete MS, Rojas Á, Fasce R, Fernández J, Mora J, Ramírez E, Gaete-Argel A, Acevedo ML, Valiente-Echeverría F, Soto-Rifo R, Weiskopf D, Grifoni A, Sette A, Zeng G, Meng W; CoronaVacCL03 Study Group; González-Aramundiz JV, Johnson M, Goldblatt D, González PA, Abarca K, Bueno SM, Kalergis AM. Gálvez NMS, et al. Among authors: rivera perez d. Elife. 2022 Oct 13;11:e81477. doi: 10.7554/eLife.81477. Elife. 2022. PMID: 36226829 Free PMC article. Clinical Trial.
Female offspring gestated in hypothyroxinemia and infected with human Metapneumovirus (hMPV) suffer a more severe infection and have a higher number of activated CD8+ T lymphocytes.
Funes SC, Ríos M, Fernández-Fierro A, Rivera-Pérez D, Soto JA, Valbuena JR, Altamirano-Lagos MJ, Gómez-Santander F, Jara EL, Zoroquiain P, Roa JC, Kalergis AM, Riedel CA. Funes SC, et al. Among authors: rivera perez d. Front Immunol. 2022 Sep 8;13:966917. doi: 10.3389/fimmu.2022.966917. eCollection 2022. Front Immunol. 2022. PMID: 36159799 Free PMC article.
A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern.
Schultz BM, Melo-González F, Duarte LF, Gálvez NMS, Pacheco GA, Soto JA, Berríos-Rojas RV, González LA, Moreno-Tapia D, Rivera-Pérez D, Ríos M, Vázquez Y, Hoppe-Elsholz G, Andrade-Parra CA, Vallejos OP, Piña-Iturbe A, Iturriaga C, Urzua M, Navarrete MS, Rojas Á, Fasce R, Fernández J, Mora J, Ramírez E, Gaete-Argel A, Acevedo ML, Valiente-Echeverría F, Soto-Rifo R, Weiskopf D, Grifoni A, Sette A, Zeng G, Meng W; CoronaVac03CL Study Group; González-Aramundiz JV, González PA, Abarca K, Kalergis AM, Bueno SM. Schultz BM, et al. Among authors: rivera perez d. mBio. 2022 Aug 30;13(4):e0142322. doi: 10.1128/mbio.01423-22. Epub 2022 Aug 10. mBio. 2022. PMID: 35946814 Free PMC article.
A booster dose of an inactivated SARS-CoV-2 vaccine increases neutralizing antibodies and T cells that recognize Delta and Omicron variants of concern.
Schultz BM, Melo-González F, Duarte LF, Gálvez NM, Pacheco GA, Soto JA, Berríos-Rojas RV, González LA, Moreno-Tapia D, Rivera-Pérez D, Ríos M, Vázquez Y, Hoppe-Elsholz G, Vallejos OP, Iturriaga C, Urzua M, Navarrete MS, Rojas Á, Fasce R, Fernández J, Mora J, Ramírez E, Gaete-Argel A, Acevedo M, Valiente-Echeverría F, Soto-Rifo R, Weiskopf D, Grifoni A, Sette A, Zeng G, Meng W; CoronaVac03CL Study Group; González-Aramundiz JV, González PA, Abarca K, Kalergis AM, Bueno SM. Schultz BM, et al. Among authors: rivera perez d. medRxiv [Preprint]. 2022 Feb 7:2021.11.16.21266350. doi: 10.1101/2021.11.16.21266350. medRxiv. 2022. Update in: mBio. 2022 Aug 30;13(4):e0142322. doi: 10.1128/mbio.01423-22 PMID: 35441179 Free PMC article. Updated. Preprint.
Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial.
Bueno SM, Abarca K, González PA, Gálvez NM, Soto JA, Duarte LF, Schultz BM, Pacheco GA, González LA, Vázquez Y, Ríos M, Melo-González F, Rivera-Pérez D, Iturriaga C, Urzúa M, Dominguez A, Andrade CA, Berrios RV, Canedo-Marroquín G, Covián C, Moreno-Tapia D, Saavedra F, Vallejos OP, Donato P, Espinoza P, Fuentes D, González M, Guzmán P, Muñoz-Venturelli P, Pérez CM, Potin M, Rojas A, Fasce R, Fernández J, Mora J, Ramírez E, Gaete-Argel A, Oyarzún-Arrau A, Valiente-Echeverría F, Soto-Rifo R, Weiskopf D, Sette A, Zeng G, Meng W, González-Aramundiz JV, Kalergis AM. Bueno SM, et al. Among authors: rivera perez d. medRxiv [Preprint]. 2021 Apr 1:2021.03.31.21254494. doi: 10.1101/2021.03.31.21254494. medRxiv. 2021. Update in: Clin Infect Dis. 2022 Aug 24;75(1):e792-e804. doi: 10.1093/cid/ciab823 PMID: 35441164 Free PMC article. Updated. Preprint.
Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Melo-González F, Soto JA, González LA, Fernández J, Duarte LF, Schultz BM, Gálvez NMS, Pacheco GA, Ríos M, Vázquez Y, Rivera-Pérez D, Moreno-Tapia D, Iturriaga C, Vallejos OP, Berríos-Rojas RV, Hoppe-Elsholz G, Urzúa M, Bruneau N, Fasce RA, Mora J, Grifoni A, Sette A, Weiskopf D, Zeng G, Meng W, González-Aramundiz JV, González PA, Abarca K, Ramírez E, Kalergis AM, Bueno SM. Melo-González F, et al. Among authors: rivera perez d. Front Immunol. 2021 Nov 9;12:747830. doi: 10.3389/fimmu.2021.747830. eCollection 2021. Front Immunol. 2021. PMID: 34858404 Free PMC article. Clinical Trial.
15 results